Efficacy and safety of firocoxib in the management of canine osteoarthritis under field conditions.
A total of 249 client-owned dogs with osteoarthritis were treated with firocoxib (5 mg/kg/day) or a positive control, etodolac (10-15 mg/kg/day), for 30 days. Veterinary examinations were performed on approximately days 0 (visit 1), 14 (visit 2), and 29 (visit 3). Based on defined noninferiority criteria, firocoxib and etodolac were comparable. Based on the magnitude of the change from baseline, improvement with firocoxib was significantly greater than with etodolac for lameness at a trot (visits 2 and 3) and for lameness at a walk, pain on manipulation, and range of motion (visit 3) (P < .05). In weekly owner evaluations, firocoxib provided significantly greater improvement than etodolac (P < .05) at each scoring.
Hanson
Peter D
PD
Merial Limited, 3239 Satellite Blvd, Duluth, GA 30096, USA.
Brooks
Kenneth C
KC
Case
Jerry
J
Conzemius
Michael
M
Gordon
Wanda
W
Schuessler
James
J
Shelley
Bert
B
Sifferman
Roger
R
Drag
Marlene
M
Alva
Roberto
R
Bell
Laura
L
Romano
Davida
D
Fleishman
Candis
C
D015107:4-Butyrolactone / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects / Q000627:therapeutic use*; D004283:Dog Diseases / Q000188:drug therapy* / Q000473:pathology; D004285:Dogs; D017308:Etodolac / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D007794:Lameness, Animal / Q000188:drug therapy; D008297:Male; D010003:Osteoarthritis / Q000188:drug therapy / Q000473:pathology / Q000662:veterinary*; D016059:Range of Motion, Articular / Q000187:drug effects / Q000502:physiology; D012449:Safety; D013450:Sulfones / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome
D000894:Anti-Inflammatory Agents, Non-Steroidal; D013450:Sulfones; D017308:Etodolac; D015107:4-Butyrolactone; C487384:firocoxib